Encompass Health Co. (NYSE:EHC) Shares Sold by Janus Henderson Group PLC

Janus Henderson Group PLC lowered its holdings in shares of Encompass Health Co. (NYSE:EHC) by 2.5% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,552,771 shares of the company’s stock after selling 40,588 shares during the period. Janus Henderson Group PLC owned approximately 1.54% of Encompass Health worth $128,143,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in EHC. Vanguard Group Inc. lifted its holdings in Encompass Health by 1.7% in the first quarter. Vanguard Group Inc. now owns 10,166,147 shares of the company’s stock worth $839,520,000 after purchasing an additional 169,113 shares during the period. Wellington Management Group LLP raised its holdings in Encompass Health by 5.8% during the fourth quarter. Wellington Management Group LLP now owns 8,215,770 shares of the company’s stock worth $548,156,000 after purchasing an additional 449,230 shares in the last quarter. TD Asset Management Inc boosted its stake in Encompass Health by 16.0% during the 1st quarter. TD Asset Management Inc now owns 2,283,674 shares of the company’s stock valued at $188,586,000 after purchasing an additional 314,488 shares in the last quarter. Massachusetts Financial Services Co. MA increased its position in shares of Encompass Health by 6.7% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,928,449 shares of the company’s stock valued at $128,666,000 after purchasing an additional 120,527 shares during the period. Finally, Brown Advisory Inc. raised its stake in shares of Encompass Health by 6.2% in the 4th quarter. Brown Advisory Inc. now owns 1,791,517 shares of the company’s stock worth $119,530,000 after buying an additional 104,847 shares in the last quarter. Institutional investors and hedge funds own 97.25% of the company’s stock.

Encompass Health Trading Up 0.8 %

Shares of Encompass Health stock traded up $0.77 during trading on Wednesday, reaching $93.50. 106,899 shares of the company were exchanged, compared to its average volume of 632,346. The business has a 50-day moving average price of $85.84 and a 200-day moving average price of $80.63. The firm has a market capitalization of $9.41 billion, a price-to-earnings ratio of 25.05, a P/E/G ratio of 1.43 and a beta of 0.89. The company has a quick ratio of 1.37, a current ratio of 1.37 and a debt-to-equity ratio of 1.14. Encompass Health Co. has a twelve month low of $57.55 and a twelve month high of $93.55.

Encompass Health Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, October 15th. Shareholders of record on Tuesday, October 1st will be issued a dividend of $0.17 per share. This represents a $0.68 dividend on an annualized basis and a yield of 0.73%. The ex-dividend date of this dividend is Tuesday, October 1st. This is a boost from Encompass Health’s previous quarterly dividend of $0.15. Encompass Health’s dividend payout ratio is 16.22%.

Insider Activity at Encompass Health

In related news, EVP John Patrick Darby sold 14,543 shares of Encompass Health stock in a transaction dated Monday, May 6th. The stock was sold at an average price of $83.94, for a total value of $1,220,739.42. Following the sale, the executive vice president now owns 84,773 shares of the company’s stock, valued at $7,115,845.62. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, EVP John Patrick Darby sold 14,543 shares of the firm’s stock in a transaction that occurred on Monday, May 6th. The stock was sold at an average price of $83.94, for a total value of $1,220,739.42. Following the completion of the sale, the executive vice president now directly owns 84,773 shares of the company’s stock, valued at $7,115,845.62. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Elissa Joy Charbonneau sold 10,000 shares of Encompass Health stock in a transaction dated Friday, May 24th. The stock was sold at an average price of $85.02, for a total transaction of $850,200.00. Following the sale, the insider now directly owns 18,594 shares of the company’s stock, valued at approximately $1,580,861.88. The disclosure for this sale can be found here. 2.10% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on EHC shares. Royal Bank of Canada upped their price target on shares of Encompass Health from $83.00 to $95.00 and gave the company an “outperform” rating in a report on Wednesday, May 22nd. Stephens reaffirmed an “overweight” rating and issued a $94.00 price target on shares of Encompass Health in a report on Wednesday, June 5th. Raymond James reaffirmed a “strong-buy” rating and set a $95.00 price objective (up from $85.00) on shares of Encompass Health in a research note on Friday, April 26th. Leerink Partnrs raised shares of Encompass Health to a “strong-buy” rating in a research report on Wednesday, July 10th. Finally, Mizuho raised their price objective on shares of Encompass Health from $93.00 to $95.00 and gave the stock a “buy” rating in a research note on Thursday, April 25th. Nine investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $96.50.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.